125 related articles for article (PubMed ID: 37735836)
1. CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
Ning Q; Yang T; Guo X; Huang Y; Gao Y; Liu M; Yang P; Guan Y; Liu N; Wang Y; Chen D
J Viral Hepat; 2023 Dec; 30(12):951-958. PubMed ID: 37735836
[TBL] [Abstract][Full Text] [Related]
2. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
[TBL] [Abstract][Full Text] [Related]
3. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
6. Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients.
Wang LP; Han FZ; Yan XB; Fan YC; Wang K
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):18-23. PubMed ID: 27894395
[TBL] [Abstract][Full Text] [Related]
7. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
9. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
10. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
11. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
12. Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma.
Gao ZY; Li T; Wang J; Du JM; Li YJ; Li J; Lu FM; Zhuang H
J Gastroenterol; 2007 Sep; 42(9):761-8. PubMed ID: 17876546
[TBL] [Abstract][Full Text] [Related]
13. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
14. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
[TBL] [Abstract][Full Text] [Related]
15. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
Sayan M; Akhan SC
Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
18. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
[TBL] [Abstract][Full Text] [Related]
19. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
[TBL] [Abstract][Full Text] [Related]
20. Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.
Lin HC; Jeng WJ; Liu J; Pan MH; Lee MH; Batrla-Utermann R; Lu SN; Chen CF; Yang HI; Chen CJ
Aliment Pharmacol Ther; 2024 Apr; 59(8):993-1002. PubMed ID: 38410882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]